SureTrader SureTrader SPDR Advertisement
Home > Boards > Canadian > Biotechs > Nuvo Research Inc. (TSX:NRI)

ST. LOUIS and MISSISSAUGA, ON, Aug. 4 /CNW/

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
AC416 Member Profile
Member Level 
Followed By 29
Posts 2,649
Boards Moderated 0
Alias Born 09/29/06
160x600 placeholder
Advertisement
Nuvo Research® Provides Update on International Licensing of Pennsaid® 2% "PR Newswire (Canada)" - 6/24/2015 7:30:00 AM
Nuvo Research® Provides Update on International Licensing of Pennsaid® 2% "PR Newswire (US)" - 6/24/2015 7:30:00 AM
Nuvo Research® Receives Health Canada Approval to Conduct New WF10™ Phase 2 Trial "PR Newswire (Canada)" - 6/8/2015 7:30:00 AM
Nuvo Research® Receives Health Canada Approval to Conduct New WF10™ Phase 2 Trial "PR Newswire (US)" - 6/8/2015 7:30:00 AM
Nuvo Research announces director election results of its Annual General Meeting "PR Newswire (Canada)" - 5/13/2015 5:00:00 PM
Nuvo Research announces director election results of its Annual General Meeting "PR Newswire (US)" - 5/13/2015 5:00:00 PM
Nuvo Research® Announces 2015 First Quarter Results "PR Newswire (Canada)" - 5/12/2015 5:00:00 PM
Nuvo Research® Announces 2015 First Quarter Results "PR Newswire (US)" - 5/12/2015 5:00:00 PM
Nuvo Research® Announces New WF10™ Phase 2 Trial "PR Newswire (Canada)" - 4/22/2015 7:30:00 AM
Nuvo Research® Announces New WF10™ Phase 2 Trial "PR Newswire (US)" - 4/22/2015 7:30:00 AM
Nuvo Research® Updates Company Strategy "PR Newswire (Canada)" - 4/16/2015 7:30:00 AM
Nuvo Research® Updates Company Strategy "PR Newswire (US)" - 4/16/2015 7:30:00 AM
Nuvo Research® Provides Business Update "PR Newswire (Canada)" - 3/5/2015 7:30:00 AM
Nuvo Research® Provides Business Update "PR Newswire (US)" - 3/5/2015 7:30:00 AM
Nuvo Research® Announces 2014 Fourth Quarter & Year-End Results "PR Newswire (Canada)" - 2/19/2015 5:00:00 PM
Nuvo Research® Announces 2014 Fourth Quarter & Year-End Results "PR Newswire (US)" - 2/19/2015 5:00:00 PM
Nuvo Research® Reports Topline Results of Phase 2 Study of WF10™ for the Treatment of Allergic Rhinitis "PR Newswire (Canada)" - 1/30/2015 7:00:00 AM
Nuvo Research® Reports Topline Results of Phase 2 Study of WF10™ for the Treatment of Allergic Rhinitis "PR Newswire (US)" - 1/30/2015 7:00:00 AM
Nuvo Research® Granted Additional U.S. Patent for Treatment of Allergic Rhinitis with WF10™ "PR Newswire (Canada)" - 12/22/2014 7:30:00 AM
Nuvo Research® Granted Additional U.S. Patent for Treatment of Allergic Rhinitis with WF10™ "PR Newswire (US)" - 12/22/2014 7:30:00 AM
Nuvo Research® reports that all patients have completed Phase 2 study of WF10™ for the treatment of allergic rhinitis "PR Newswire (Canada)" - 12/18/2014 7:30:00 AM
Nuvo Research® reports that all patients have completed Phase 2 study of WF10™ for the treatment of allergic rhinitis "PR Newswire (US)" - 12/18/2014 7:30:00 AM
Nuvo Research® reacquires Pennsaid® 2% rights to South America, Central America, South Africa and Israel "PR Newswire (Canada)" - 11/13/2014 7:30:00 AM
Nuvo Research® reacquires Pennsaid® 2% rights to South America, Central America, South Africa and Israel "PR Newswire (US)" - 11/13/2014 7:30:00 AM
Nuvo Research® Announces 2014 Third Quarter Results "PR Newswire (Canada)" - 11/10/2014 5:00:00 PM
AC416 Member Level  Tuesday, 08/04/09 10:52:08 PM
Re: None
Post # of 82 
ST. LOUIS and MISSISSAUGA, ON, Aug. 4 /CNW/ - Covidien (NYSE:COV - News), a leading global provider of healthcare products, and Nuvo Research Inc. (TSX:NRI - News), a Canadian drug development company, today announced that the U.S. Food and Drug Administration (FDA) has set a new action date under the Prescription Drug User Fee Act (PDUFA) for Pennsaid (diclofenac sodium) topical solution 1.5% w/w of November 4, 2009.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist